Dennis Ding
Stock Analyst at Jefferies
(n/a)
# 4,373
Out of 4,735 analysts
11
Total ratings
n/a
Success rate
-27.19%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dennis Ding
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IKT Inhibikase Therapeutics | Initiates: Buy | $8 | $2.81 | +184.70% | 1 | Nov 8, 2024 | |
| ASMB Assembly Biosciences | Upgrades: Buy | $2 → $35 | $14.30 | +144.76% | 1 | Sep 20, 2024 | |
| FOLD Amicus Therapeutics | Initiates: Buy | $18 | $9.51 | +89.27% | 1 | Sep 6, 2024 | |
| ABUS Arbutus Biopharma | Maintains: Buy | $5 → $7 | $3.21 | +118.07% | 2 | Sep 5, 2024 | |
| RXRX Recursion Pharmaceuticals | Maintains: Hold | $8 → $6 | $6.88 | -12.79% | 1 | Sep 3, 2024 | |
| LYRA Lyra Therapeutics | Downgrades: Hold | $10 → $0.5 | $0.19 | +159.74% | 1 | May 7, 2024 | |
| CARA Cara Therapeutics | Reiterates: Buy | $216 | $4.60 | +4,595.65% | 1 | Jun 27, 2023 | |
| CORT Corcept Therapeutics | Downgrades: Hold | $35 → $22 | $61.11 | -64.00% | 1 | Feb 15, 2023 | |
| NAMS NewAmsterdam Pharma Company | Initiates: Buy | $24 | $23.70 | +1.27% | 1 | Dec 19, 2022 | |
| ROIV Roivant Sciences | Initiates: Buy | $10 | $11.27 | -11.27% | 1 | Oct 26, 2021 |
Inhibikase Therapeutics
Nov 8, 2024
Initiates: Buy
Price Target: $8
Current: $2.81
Upside: +184.70%
Assembly Biosciences
Sep 20, 2024
Upgrades: Buy
Price Target: $2 → $35
Current: $14.30
Upside: +144.76%
Amicus Therapeutics
Sep 6, 2024
Initiates: Buy
Price Target: $18
Current: $9.51
Upside: +89.27%
Arbutus Biopharma
Sep 5, 2024
Maintains: Buy
Price Target: $5 → $7
Current: $3.21
Upside: +118.07%
Recursion Pharmaceuticals
Sep 3, 2024
Maintains: Hold
Price Target: $8 → $6
Current: $6.88
Upside: -12.79%
Lyra Therapeutics
May 7, 2024
Downgrades: Hold
Price Target: $10 → $0.5
Current: $0.19
Upside: +159.74%
Cara Therapeutics
Jun 27, 2023
Reiterates: Buy
Price Target: $216
Current: $4.60
Upside: +4,595.65%
Corcept Therapeutics
Feb 15, 2023
Downgrades: Hold
Price Target: $35 → $22
Current: $61.11
Upside: -64.00%
NewAmsterdam Pharma Company
Dec 19, 2022
Initiates: Buy
Price Target: $24
Current: $23.70
Upside: +1.27%
Roivant Sciences
Oct 26, 2021
Initiates: Buy
Price Target: $10
Current: $11.27
Upside: -11.27%